What is Prime Medicine's unrealized gains on investments?

Prime Medicine (PRME) reported unrealized gains on investments of $12K in Q1 2026.

Prime Medicine PRME Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

PrecigenPGEN

——

Viridian Therapeutics, Inc.VRDN

——

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's unrealized gains on investments?: Prime Medicine (PRME) reported unrealized gains on investments of $12K in Q1 2026.